Claims for Patent: 7,449,192

✉ Email this page to a colleague

Summary for Patent: 7,449,192

Title:	Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
Abstract:	The present invention related to methods for treating neurological-urological conditions, including neurogenic bladder dysfunction. This is accomplished by administration of a botulinum toxin into the lower urinary tract of a patient with a neurogenic bladder dysfunction, including the bladder or urinary sphincter and the bladder wall.
Inventor(s):	Schmidt; Richard A. (Arvada, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	10/778,924
Patent Claims:	1. A method for treating a patient with a neurogenic bladder dysfunction, said method comprising the step of injecting a therapeutically effective amount of botulinum toxin type A into the lateral bladder wall of a patient with said neurogenic bladder dysfunction, thereby treating a symptom of said neurogenic bladder dysfunction. 2. The method of claim 1, wherein said neurogenic bladder dysfunction is secondary to a disease condition selected from the group consisting of Parkinson's disease, a spinal cord injury, a stroke, multiple sclerosis, and a spasm reflex. 3. The method of claim 1, wherein the step of injection comprises a single injection. 4. The method of claim 1, wherein the step of injection comprises injecting a gel comprising the botulinum toxin. 5. The method of claim 1, wherein the step of injecting results in increased bladder capacity. 6. The method of claim 1, wherein the therapeutically effective amount of botulinum toxin type A is up to 2500 units. 7. The method of claim 1, wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A. 8. The method of claim 1, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

Details for Patent 7,449,192

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	7,449,192	2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	7,449,192	2017-07-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,449,192

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483	⤷ Subscribe
United States of America	9066943	⤷ Subscribe
United States of America	8840905	⤷ Subscribe
United States of America	8062643	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.